with any risk reduction in disability progression at 18 months (OR 1.23, 95% CI 0.43 to 3.56). Risk of experiencing at least one exacerbation at end of follow-up was not significantly reduced with corticosteroid treatment (OR 0.36; 95% CI 0.10 to 1.25).
Only one study recorded adverse events: in one patient i. v. MP was discontinued after the fourth pulse when he developed acute glomerulonephritis; a second patient was removed from the study after the fifth i. v. MP pulse because of severe osteoporosis.
Authors' conclusions
There is no enough evidence that long-term corticosteroid treatment delays progression of long term disability in patients with MS. Since one study at high risk of bias showed that the administration of pulsed high dose i. v. MP is associated with a significant reduction in the risk of long term disability progression in patients with RR MS, an adequately powered, high quality RCT is needed to investigate this finding.
P L A I N L A N G U A G E S U M M A R Y

The long-term use of anti-inflammatory corticosteroids for treating multiple sclerosis
Multiple sclerosis is an inflammatory disease affecting the brain and spinal cord. It results in episodes of neurological deficit which recover (relapses) as well as accumulation of sustained disability with the passage of time. Corticosteroids are potent anti-inflammatory drugs. It is postulated that long-term use of steroids may reduce the accumulation of disability. The reviewers found three studies addressing this issue. A meta-analysis showed a trend towards a beneficial effect of long-term corticosteroids on accumulation of disability; however only two small studies contributed to this result. It was not possible to reliably comment on the effect of long-term corticosteroids on the frequency of relapses. Side effects were poorly documented. Therefore rigorous randomised controlled trials of this treatment are warranted.
B A C K G R O U N D
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system whose aetiology is still unknown. Treatment is based on the assumption that autoimmunity plays a major role in the pathogenesis of disease (Compston 2002; Rizvi 2004a; Rizvi 2004b; Frohman 2005) .
Corticosteroids inhibit lymphocyte proliferation and the synthesis of most known proinflammatory cytokines and cell surface molecules required for immune function with a mechanism that involves a specific corticosteroid receptor (Sloka 2005) . Because of their potent anti-inflammatory effects, corticosteroids have been used to treat MS patients since the 1950s and today are considered the standard treatment for acute exacerbations (Compston 2002; Rizvi 2004b; Frohman 2005) . However, corticosteroids, being immunosuppressive drugs, might prevent or delay the occurrence of future episodes of inflammatory demyelination (Gold 2001) .
A previous Cochrane review showed that a short term high dose intravenous methylprednisolone (i. v. MP) course within 8 weeks of acute exacerbation of MS, improved symptoms and short term disability without significant side effects but data were insufficient to estimate the effect on prevention of new exacerbations and reduction of long term disability (Filippini 2000) . In the present review we wanted to consider long term corticosteroid treatment to specifically prevent disease progression rather than to treat acute exacerbations.
The idea that corticosteroids might prevent new exacerbations, reduce long term disability, and therefore modify the natural history of MS, comes from several observations:
• the initial results of the Optic Neuritis Treatment Trial suggested that treatment of a first episode of optic neuritis with a single course of i. v. MP followed by a tapering course of oral prednisone, reduced the 2 year rate of development of clinically definite MS (Beck 1993) , although this effect was lost on further follow-up extending to 4 years (Beck 1995);
• a phase II randomised controlled trial (RCT) in relapsingremitting (RR) MS comparing the efficacy of repeated pulsed i. v. MP with i. v. MP at the same dosage regimen but administered only for relapses, showed that pulsed i. v. MP slowed the development of destructive lesions (T1 black holes), the rate of whole-brain atrophy progression and the development of sustained physical disability (Zivadinov 2001);
• another phase II RCT of bimonthly i. v. MP pulses in patients with secondary progressive (SP) MS showed a beneficial effect on time to onset of sustained progression of disability with the high-dose regimen (Goodkin 1998a);
• one non randomised trial with historical controls suggested that patients with MS treated with high dose i. v. corticosteroids during six months post-partum might reduce the childbirthassociated risk of acute exacerbation (de Seze 2004);
• some studies indicated that pulsed i. v. MP produced a rapid and dose dependent reduction in gadolinium enhancement on cerebral MRI that lasted for up to 6 months ( Gasperini 1997; Goodkin 1998b; Smith 1993; Barkhof 1994) .
In a systematic review (Brusaferri 2000) that included around 500 randomised patients comparing the effects of adrenocorticotrophic hormone (ACTH), prednisolone or MP (with or without azathioprine) versus placebo, no significant effect on longterm disability and relapse prevention was noted. However this meta-analysis included studies in which these agents were given for as little as 5-30 days. The review also reported the occurrence of both minor and major side effects, the latter including severe Cushing's syndrome, hypertension, herpes simplex, herpes zoster, severe ankle oedema, femoral fracture and gastrointestinal bleeding, but these occurred with ACTH or an azathioprine/methylprednisolone combination (Brusaferri 2000) .
Pulsed regimens of administration have renewed interest in corticosteroids as they are reported to be well-tolerated and safe, with only minor and dose-related side effects, such as insomnia, transient mood disorders, acneiform-rash, heartburn, headache and myalgias (Pozzilli 2004) . The rationale for repeated pulsed administration is based on the hypothesis that these drugs may have a long-lasting immunosuppressive effect, as indicated by the above mentioned studies, and that MS may be a restless, progressive disease even when, as in the RR form, the clinical course between two exacerbations is stable (Stone 1995).
Thus, a systematic review of RCT to gather all data available to date on long term use of corticosteroids appeared worthwhile.
O B J E C T I V E S
The objective of this review was to determine whether long term treatment of MS patients with corticosteroids: 1) prevents or significantly delays disability progression at long term follow-up;
2) reduces the risk of exacerbations, increasing the proportion of relapse-free patients during follow-up;
3) is well tolerated and safe.
We selected progression of disease rather than the occurrence of exacerbations as the primary outcome measure, both because the frequency of exacerbations does not necessarily correlate with clinical evidence of disease progression (Confavreux 2000), a more meaningful parameter than the occurrence of symptoms and signs that can remit, and because we also wanted to consider progressive forms of the disease.
We also wanted to evaluate the effect of different doses, drugs, routes of administration, regimens (i.e. pulsed or continuous), length of treatment and whether the effect of treatment was different according to types of disease (relapsing/remitting, relapsing/progressive [RP] , secondary progressive or primary progressive [PP]).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We planned to consider all apparently unconfounded RCTs, with or without blinding, of long term treatment with corticosteroids in MS.
Types of participants
Patients with definite MS according to clinical and paraclinical diagnostic criteria (Poser 1983; McDonald 2001; Polman 2005) irrespective of their disease course (RR, RP, SP or PP). Studies describing only clinical criteria were accepted as well (McDonald 1977) .
Types of interventions
Active treatment: long term courses (i.e. longer than 6 months) of any type of corticosteroid, continuous or intermittent, provided that they were not started for relapses (i.e. started more than 2 months after a relapse), whatever the administration route and dosage. Control: placebo or no treatment. Short courses (i.e. maximum 21 days of duration) of corticosteroids were permitted, provided they were administered for relapses.
We studied the following outcome measures in either treatment group at 1 and 2 years and at the end of the scheduled follow-up period: Primary outcome 1. Patients who progressed. Whenever unspecified, progression was defined as a persistent worsening of at least one point in EDSS (Kurtzke 1983), recorded whilst not in relapse. However, other definitions of progression were accepted, including a persistent half-point increase starting from EDSS score 5.5, as is often reported in the literature. Safety Safety outcome was assessed among primary endpoints by unique measures incorporating all events occurring throughout the trials: 1. Number of patients with severe side effects. If not otherwise specified, side effects were defined as severe when leading to one of the following: death, hospitalisation, treatment discontinuation. 2. Extraction of any available information about safety in both corticosteroid and control groups.
Secondary outcomes
2. Patients experiencing at least one exacerbation, which was defined as the acute or subacute appearance/reappearance of neurological signs and symptoms for at least 24 hours, in the absence of fever or infection. 3. Relapse free survival, if available.
Search methods for identification of studies
One reviewer (FB) provided references pertinent to this review already retrieved in the course of two previous systematic reviews on corticosteroids for multiple sclerosis which he had co-authored (Brusaferri 2000; Filippini 2000) . The same search strategy was used in this review to update searches.
Electronic searches
The search strategy we used was drawn from the one developed by the Multiple Sclerosis Group. Relevant trials were identified searching the following sources: Papers in any language were accepted provided they met the criteria specified above.
Searching other resources
4. Reference lists of studies on corticosteroid treatment for MS 5. Abstracts of neurological and multiple sclerosis congresses and symposia, conference proceedings, dissertations and other forms of reports where trials relevant to the review are likely to have been published 6. We searched for unpublished studies by contacting researchers who were known to be involved in this field 7. We contacted Pfizer Inc, who had acquired Upjohn, a company which was known to have an interest in the use of steroids in MS, in order to identify any unpublished data.
Data collection and analysis
Selection of studies
The contact reviewer (AC) divided the search results between coreviewers (SB, FB, IG, CS and AP) who decided separately which articles to retrieve. Abstracts of references with titles of interest were examined to determine relevance. When the abstract suggested relevance, or relevance was unclear from the abstract, or where no abstract was available, a copy of the article was obtained. Copies of articles identified in reference lists of papers related to the use of corticosteroid treatment in MS were also obtained. Trained reviewers (AC and FB) verified that the papers thus selected adhered to the inclusion criteria. AC and FB were not blinded to the names of the authors, their institutions, the journal, or the journal publisher. Disagreements were resolved by discussion between the two reviewers. All studies meeting the inclusion criteria were summarized in the table Characteristics of Included Studies.
Assessment of methodological quality
Each reviewer (AC, SB, FB, IG, AP and CS) separately extracted information, for each included trial, regarding the method of randomisation, blinding of outcome evaluators, and whether all the randomised patients were accounted for in the analysis. One reviewer (AC) contacted the authors of the trials if the above information was not available in the published reports. In the case of an unpublished study (BPSM 1995) this information was extracted from the protocol approved by local Ethics Committee in 1995. Since two reviewers (AC and SB) had a leading role in such study, they did not participate to the assessment of methodological quality. Reviewers assessed the quality of the trials independently and were asked to fill in a form shown in Table 1 that was then sent to the contact reviewer (AC). Concealment of allocation (telephoning to a central office, first entering the data into a computer, the pharmacy, using identical numbered containers, or sequential, sealed, opaque envelopes), blinding in outcome evaluation and intention-to-treat analysis were evaluated and graded as present, absent or unclear. The included studies were categorised into one of three quality categories (protection against bias), based on those described in the Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 (section 6.7.1): A (low risk of bias, all of the criteria present), B (moderate risk of bias, one or more criteria unclear), C (high risk of bias, one or more criteria absent) (Higgins 2005) . We planned to summarise the interobserver agreement in the overall quality score using the weighted kappa statistic.
Data extraction
All the reviewers (AC, SB, FB, IG, AP and CS) independently extracted data for outcome and safety assessments according to measures defined in the 'Types of outcome measures' section, filling a form shown in Table 2 . Forms were then sent to the contact reviewer (AC) who summarized the data. The same forms were used to ask original authors for unpublished data. We planned to use intention-to-treat analysis, extracting the number of patients originally allocated to each treatment group irrespective of compliance. When numbers extracted by two or more reviewers varied, differences were resolved by discussion.
Data analysis
The efficacy analyses were based on the results of the individual trials for disability at one year or more after treatment initiation and the safety analyses on the results for severe side effects. The analyses on secondary outcomes and on minor side effects were used to support the data on primary outcomes. A weighted estimate of the treatment effects across trials (odds ratio) was calculated using a fixed effect model. For interpreting the results, 95% confidence intervals were used. Heterogeneity across studies was quantified using I 2 , i.e. by describing the percentage of the variability in the effect estimates that is due to heterogeneity rather than sampling error. A value greater than 50% was considered substantial heterogeneity. (Higgins 2002) Sensitivity analyses If patients were excluded or lost to follow up after randomisation, further information was sought by correspondence with the trialists. If the data about these patients remained unavailable, a worstcase scenario analysis for the outcome of "disability progression" was undertaken to ensure significance of the results. In this analysis, it was assumed that those patients who were lost to follow up in the treatment group had the worst outcome while those patients who were lost to follow up in the control group had the best outcome. We planned to make a definite conclusion about the treatment effectiveness if the effects of primary and worst-case meta-analyses were in the same direction and magnitude.
Subgroup analyses
If substantial heterogeneity was found on efficacy analysis, we planned to explore this heterogeneity using the following subgroup analyses:
(1) comparison of trials with quality A with trials with quality B or C; (2) comparison of the efficacy of treatment in patients treated within one year versus those treated after one year of MS onset; (3) comparison of the effect of different doses, drugs, routes of administration, regimens (i.e. intermittent or continuous) and length of treatment; (4) comparison of the efficacy of treatment in RR, RP, SP or PP patients We planned to use the overlap of the confidence intervals of the summary estimates in the groups of comparison (lack of overlap between confidence intervals indicating statistical significance).
R E S U L T S Description of studies
We identified 2270 articles (previous systematic reviews 111; CENTRAL 170; MEDLINE 1741; EMBASE 242 ; hand searching 4; unpublished 2; drug manufacturers zero). Ten possible RCTs involving long-term administration of steroids in MS were selected by reviewers on the basis of inclusion criteria after reading the abstracts. We excluded seven studies after reading the full published papers: one study was a dose-comparison trial of i. v. MP without a control group (Goodkin 1998a), two studies used MRI parameters as outcome measures ( 
Data availability
One study was unpublished (BPSM 1995) because it was prematurely interrupted for organisational problems and lack of funding. This study's data were made available by one of the reviewers (SB) and checked by a second reviewer (CS). The other two RCTs were published as full papers. However, since the exact number of patients with disability worsening and experiencing exacerbations during follow-up could not be extracted from the Zivadinov 2001 paper, this information was obtained by contacting the authors.
Type of interventions and patients
Both the BPSM 1995 and Zivadinov 2001 studies used pulsed high dose i. v. MP in RR MS whilst the study by Miller 1961 used continuous oral prednisolone in patients with "slowly progressive", "fluctuant" and "rapidly progressive" MS (diagnostic criteria were not given). Patients in the control group were allowed to be treated with corticosteroids in case of exacerbation in two studies (BPSM 1995; Zivadinov 2001) but in one of them (BPSM) the occurrence of a relapse automatically ended the study for individual patients (see "Outcomes definition" in this paragraph for further details). Treatment duration was 18 months in the Miller 1961 study, 5 years in the Zivadinov 2001 study and two years or until the first relapse in the BPSM 1995 (see table of included studies).
Baseline characteristics
Equivalence between the treatment and control group in the baseline participants' characteristics was present in the three selected RCTs. (see table of characteristics of included studies). To extract data on progression of disability we used the reported number of patients who "deteriorated" at the "patients' own assessment" at 18 month (that outcome was divided in "improved", "deteriorated" and "remained unchanged" in the paper), making due allowance for the potential biases involved in such definition. "Acute exacerbation" was not defined and data was reported for individual relapses rather than for the number of patients experiencing at least one exacerbation. Since we could not get further clarification about acute relapses in the Miller study we could not consider such study for analysis on prevention of new exacerbations. -In the BPSM 1995 study, progression of disability was defined but patients were not followed-up after the first exacerbation, contrary to what was planned. Since patients not experiencing a relapse in the two years of the study were just 2, we did not have any data on long-term disability progression for the majority of the patients. -The Zivadinov 2001 study defined progression of disability as at least a 1.0-point worsening from baseline for patients who entered at or below an EDSS score of 5.0 or a 0.5-point worsening from baseline for patients who entered at an EDSS score of 5.5. Worsening was required to persist for at least two consecutive 4-month visits during the first 3 years of the study or at least two consecutive 6-month visits during the fourth and fifth years of the study. Relapses were defined as the appearance or reappearance of one or more symptoms, attributable to MS, accompanied by objective deterioration on neurologic examination, lasting at least 24 hours, in the absence of fever, preceded by neurologic stability for at least 30 days and in the absence of steroid withdrawal within 60 days of the new event.
Outcomes definition -The Miller 1961study used different clinical outcome measures
Risk of bias in included studies
Randomisation and concealment allocation The method of randomisation was centralised, providing adequate concealment of allocation in two trials (BPSM 1995; Zivadinov 2001) : in the BPSM 1995 study randomisation and allocation were generated by computer by personnel not involved in patients management and in the Zivadinov 2001 study this was done by a statistician "who had no contact with the study subjects". In the Miller 1961 the method of randomisation was classified as "unclear" by all the reviewers independently, since the method of randomisation was not described. Blinding The BPSM 1995 and Miller 1961studies were double blinded. During the Zivadinov 2001 study blindness to treatment of patients and clinical examiners was not warranted (although participants did not know the allocation group into which they will have been allocated at the randomisation step); radiologists conducting image analysis were blinded. Intention-to-treat analysis, excluded and losses to follow-up An intention-to-treat analysis was impossible for all the three trials. In the BPSM 1995 study the intention to treat analysis was planned but not performed and there were 10 patients (7 treated) lost to follow-up (28% overall). Moreover, patients experiencing an exacerbation were not followed up although a two year followup was planned. In the Zivadinov 2001 and Miller 1961 trials a total of 11 participants (7% overall) were excluded after randomisation or lost to follow-up (see details in table of included studies). No information was available on the outcome measures in these participants. Overall assessment of validity The three included RCTs were classified at high risk of bias (see table of included studies). The inter-observer agreement in the overall quality score was not summarised with the kappa statistic since there was a 100% agreement among the reviewers.
Effects of interventions
A total of 183 (91 treatment, 92 control) out of 210 randomised participants were considered (27 patients assigned to calcium aspirin in the Miller 1961study were excluded from the analysis). PREVENTION OF DISABILITY WORSENING (PRIMARY OUTCOME) (1) at the end of follow up Data from 2 trials (Miller 1961; Zivadinov 2001) with 136 participants, 74% of participants included in the review) were available on this outcome. Corticosteroid therapy was associated with a non significant reduction in the risk of being worse at the end of follow-up (odds ratio [OR] 0.51, 95% confidence interval [CI] 0.26 to 1.02). There was substantial heterogeneity between the two trials (I 2 : 78.4%). (2) at the end of follow up: sensitivity analysis Since information on patients excluded and lost to follow-up was unavailable, a worst case scenario was carried out as pre-specified. Such analysis, performed by considering patients who were randomised to treatment and then excluded as worst outcome events, did not significantly change the result (number of events in treated = 30/72; number of events in controls = 37/75; OR 0.74, 95% CI 0.39 to 1.41) and confirmed the inconsistency across the two studies (I 2 : 73.7%).
(3) at one year Only data from the Zivadinov 2001 study was available, on 81 patients. Corticosteroid therapy was associated with a non significant reduction in the risk of being worse at 1 year of follow-up (OR 0.16, 95% CI 0.02 to 1.38). (4) at one year: sensitivity analysis Sensitivity analysis of the 88 patients originally randomised did not change the result (OR 0.86, 95% CI 0.24 to 3.04).
(5) at two years Only data from the Zivadinov 2001 study was available, on 81 patients. Corticosteroid therapy was associated with a significant reduction in the risk of being worse at 2 years of follow-up (OR 0.09, 95% CI 0.02 to 0.42). In absolute terms this means that 330 patients for every 1000 treated (95% CI 170 to 490) avoided disability progression after two years of treatment. (6) at two year: sensitivity analysis Treatment was still associated with a favourable outcome in the worst case scenario (OR 0.29, 95% CI 0.10 to 0.85). (7) subgroup analysis Subgroup analysis was performed since there was substantial heterogeneity after efficacy analysis on disability progression at the end of follow-up. Such analysis should be regarded as a qualitative rather than quantitative description, since the RCTs considered were just two (Miller 1961; Zivadinov 2001) . Taking into account the pre-specified issues for subgroup analyses, the two trials did not differ for quality but they did for type of drug (MP versus prednisolone respectively), route of administration (i. v. versus oral), regimen (intermittent versus continuous), length of treatment (5 years versus 1 year and a half ), disease course (RR versus variable course), disability progression definition (objective versus patients' own assessment in the Miller 1961study) and mean disease duration before entry into the study (6 years versus 12 years). I. v. periodic high dose MP was associated with a significant reduction in the risk of disability progression at 5 years in RR MS (OR 0.26, 95% CI 0.10 to 0.66) (Zivadinov 2001), while oral continuous low dose prednisolone was not associated with any risk reduction in disability progression at 18 months (OR 1.23, 95% CI 0.43 to 3.56) (Miller 1961) . In absolute terms, 320 patients for every 1000 treated with pulsed high dose i. v. MP (95% CI 110 to 520) avoided long term disability progression according to the Zivadinov study. PREVENTION OF NEW EXACERBATION (SECONDARY OUTCOME) (1) At the end of follow-up Data from two trials (BPSM 1995; Zivadinov 2001) with 107 participants (59% of participants included in the review) was available on this outcome. Risk of experiencing at least one exacerbation was not significantly reduced with corticosteroid treatment (OR 0.36; 95% CI 0.10 to 1.25). No substantial heterogeneity across studies was observed (I 2 : 0%). (4) Exacerbation-free time No data was available from the 3 trials included in the review on this outcome. ADVERSE EVENTS (1) Severe adverse events In the Miller 1961, study adverse events were poorly described and two patients allocated corticosteroids were withdrawn because of hypertension. No other severe adverse effects were reported in either treatment group. In the Zivadinov 2001, study 2 patients dropped out in the pulsed i. v. MP arm: in one, i. v. MP was discontinued after the fourth pulse when the patient developed acute glomerulonephritis; the second patient was removed from the study after the fifth i. v. MP pulse because of severe osteoporosis. Twenty-five patients in the i. v. MP arm and 18 patients in the control arm were followed up 21 months after the study with bone mineral densitometry: a further patient in the pulsed i. v. MP arm and one in the control arm developed osteoporosis (Zorzon 2005). There were no fractures throughout the study. In the BPSM 1995 study no severe adverse effects were reported but 7 out of 19 patients (37%) in the pulsed i. v. MP arm versus 3 out of 17 in the control arm (18%) dropped out for unspecified reasons.
(2) Minor adverse events Almost all patients treated with i. v. MP in the Zivadinov 2001 study experienced "metallic taste" after the bolus. Insomnia, pyrosis, anxiety, constipation, acneiform rash, and polyphagia were frequently reported in both treated and control groups and did not require treatment. In the Zivadinov 2001 study the following long term events that did not require discontinuation of the planned therapy were reported without specifying the treatment group: osteoporosis (2 patients), arterial hypertension (1 patient), and recurrent herpetic infections (1 patient). In the BPSM 1995 study careful monitoring of minor adverse events was also planned but not performed. In the Miller 1961 study minor adverse events were not reported.
D I S C U S S I O N
Progression of disability
A meta-analysis was not possible for this outcome at one or two years since data was unavailable. Meta-analysis of two studies for this outcome at the end of follow up showed a trend towards a significant effect in favour of steroids, but it is possible that the substantial heterogeneity between studies diluted the effect of one of them. Indeed, on the basis of the Zivadinov 2001 study, periodic high dose i. v. MP significantly prevents progression of long term disability in patients with RRMS . To quantify the result in terms of number needed to treat, 3 patients (95% CI 2 to 9) need to be treated to avoid disability progression in one. This result seems quite robust as the effects of primary and worst-case meta-analyses are in the same direction and magnitude. The effect of i. v. MP is evident from the second year of treatment and is maintained at least until the fifth year of treatment.
As opposed to pulsed high dose i. v. MP, continuous low dose treatment with oral prednisolone did not show any effect neither on disability progression nor on prevention of new exacerbations. The use of corticosteroid therapy in the control group in the Zivadinov 2001study could be another cause of heterogeneity. However, this should have hampered rather than favoured the effect of corticosteroid in the active treatment group in the Zivadinov 2001 study.
Prevention of acute exacerbation
The secondary objective of this review was to evaluate the effect of treatment on prevention of acute exacerbations. Although one more RCT could be included (BPSM 1995) for this analysis, many patients were lost to follow up in this study. I. v. MP did not protect against the occurrence of relapses during the period studied.
[the available evidence was extremely weak since many patients were lost to follow up in this study. Data was not sufficient to determine the effect of corticosteroid treatment on prevention of exacerbations; alternatively it could well be that long-term corticosteroids do not prevent exacerbations.]
Adverse events
Only one study (Zivadinov 2001) included in this review formally recorded adverse events following corticosteroid treatment but the list may be incomplete; consequently the lack of evidence cannot be construed as paucity of adverse events.
Oral corticosteroids cannot be administered continuously at cumulative doses equivalent to pulsed regimens because of side effects mostly osteoporosis (Zorzon 2005) . This, together with the negative results from the Miller 1961 study, shift the risk-to-benefit ratio against continuous oral corticosteroid therapy. Compared to pulsed i. v. MP, there is therefore less evidence favouring further study in RCTs. As regards periodic high dose i. v. MP, although it emerged as effective from the present review, routine use in clinical practice is not yet indicated because the evidence comes from a single small study that was classified at high risk of bias and was not open to intention-to-treat analysis. Therefore the evidence cannot be considered conclusive but rather suggestive of possible efficacy. Larger RCTs of pulsed i. v. MP are warranted. Due to the reported lack of difference between oral and i. v. routes of equivalent high doses of methylprednisolone (Alam 1993), RCTs of pulsed oral high dose MP are also warranted.
A U T H O R S ' C O N C L U S I O N S Implications for practice
There is no enough evidence to justify the routine use of long term corticosteroids treatment for MS patients. This is because only three trials, all classified at high risk of bias, contributed to this review.
Implications for research
This review is suggestive of a favourable effect of long term use of pulsed high dose i. v. MP that could modify the disease course in RR MS patients. Since it is possible that such an effect is statistically and clinically significant without severe adverse effects as compared to other treatments like interferon beta (Rice 2001) or mitoxantrone (Martinelli 2005) , a large and high quality randomised controlled trial is urgently needed to test the efficacy of pulsed high dose i. v. MP.
No marketing interest may economically sustain the execution of RCTs on corticosteroids today. Moreover the planning of placebocontrolled RCTs may be considered unethical when drugs for the treatment of MS are available. Therefore, the comparison of pulsed
C H A R A C T E R I S T I C S O F S T U D I E S Characteristics of included studies [ordered by study ID]
BPSM 1995
Methods C = randomisation by computer. Double-blind. Losses to follow-up: 10 (7 assigned MP). 
Participants
Miller 1961
Methods C = not described. Double-blind. Losses to follow-up: 7 (3 assigned Prednisolone, 1 on "dummy" tablets and 3 on calcium aspirin) Participants Single center in UK; 86 patients with "slowly progressive", "fluctuant" and "rapidly progressive" MS (diagnostic criteria not described). 47 (55%) female Mean age 33yr.
Interventions Rx: 29 patients on oral prednisolone tablets 15 mg/day for 8 months then 10 mg/day for 10 months Rx: 27 patients on 9 calcium aspirin tablets (54 g)/day Control: 30 patients on a correspondent number of "dummy" tablets Dropped out/excluded after randomisation n=? n=?
Pts who progressed* at 1 yr n=? n=?
Pts who progressed* at 2 yrs n=? n=?
